Literature DB >> 2629505

Corynebacterium pseudotuberculosis infection in goats. IX. The effect of vaccination against natural infection.

G Holstad.   

Abstract

A vaccination trial was carried out in 10 infected herds. The trial included 247 female kids, the number of animals in each herd varying from 15 to 38. About half of the animals in each herd were vaccinated twice at 3 to 4 week intervals, the first vaccination being carried out before the age of 4 months. A combination of a crude filtrate of C. pseudotuberculosis toxoid with whole organisms, was used. Overall, the prevalence of animals with superficial swellings was higher in the unvaccinated than in the vaccinated group during the first 1-2 years following immunization. However, in some herds superficial swellings were as common in vaccinated as in unvaccinated animals. An antibody response following vaccination was demonstrated in the hemolysis inhibition test, but not in the bacterial agglutination test. Superficial swellings were more common in vaccinated animals which were negative than in animals which were positive in the hemolysis inhibition test at 1 1/2 months after vaccination. The vaccine used in the present study, was not sufficiently efficacious to be recommended as the only protective measure against caseous lymphadenitis in Norwegian goat herds.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2629505      PMCID: PMC8142168     

Source DB:  PubMed          Journal:  Acta Vet Scand        ISSN: 0044-605X            Impact factor:   1.695


  14 in total

1.  Corynebacterium pseudotuberculosis infection in goats. VII. Clinical, pathological, serological and hematological changes after subcutaneous inoculation of the organism.

Authors:  G Holstad; J Teige
Journal:  Acta Vet Scand       Date:  1988       Impact factor: 1.695

2.  Corynebacterium pseudotuberculosis infection in goats. I. Evaluation of two serological diagnostic tests.

Authors:  G Holstad
Journal:  Acta Vet Scand       Date:  1986       Impact factor: 1.695

3.  Corynebacterium pseudotuberculosis infection in goats. III. The influence of age.

Authors:  G Holstad
Journal:  Acta Vet Scand       Date:  1986       Impact factor: 1.695

4.  Prevalence and distribution of caseous lymphadenitis in feral goats.

Authors:  R G Batey; C M Speed; C J Kobes
Journal:  Aust Vet J       Date:  1986-02       Impact factor: 1.281

5.  Comparison of protection induced in lambs by Corynebacterium pseudotuberculosis whole cell and cell wall vaccines.

Authors:  K A Brogden; R C Cutlip; H D Lehmkuhl
Journal:  Am J Vet Res       Date:  1984-11       Impact factor: 1.156

6.  An abbatoir survey of the prevalence of caseous lymphadenitis in feral goats in Western Australia.

Authors:  V M Anderson; M E Nairn
Journal:  Aust Vet J       Date:  1985-11       Impact factor: 1.281

7.  Efficacy of Corynebacterium pseudotuberculosis bacterin for the immunologic protection of sheep against development of caseous lymphadenitis.

Authors:  B R LeaMaster; D T Shen; J R Gorham; C W Leathers; H D Wells
Journal:  Am J Vet Res       Date:  1987-05       Impact factor: 1.156

8.  Corynebacterium pseudotuberculosis infection in goats. II. The prevalence of caseous lymphadenitis in 36 goat herds in Northern Norway.

Authors:  G Holstad
Journal:  Acta Vet Scand       Date:  1986       Impact factor: 1.695

9.  Corynebacterium pseudotuberculosis infection in goats. IV. Course of the infection in two recently infected goat herds.

Authors:  G Holstad
Journal:  Acta Vet Scand       Date:  1986       Impact factor: 1.695

10.  Use of a toxoid vaccine to protect goats against intradermal challenge exposure to Corynebacterium pseudotuberculosis.

Authors:  C C Brown; H J Olander; E L Biberstein; S M Morse
Journal:  Am J Vet Res       Date:  1986-05       Impact factor: 1.156

View more
  1 in total

1.  Control of caprine arthritis-encephalitis virus and Corynebacterium pseudotuberculosis infection in a Norwegian goat herd.

Authors:  K Nord; G Holstad; L O Eik; H Grønstøl
Journal:  Acta Vet Scand       Date:  1998       Impact factor: 1.695

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.